Rodriguez Cristina, Rivera Rubi Lesbia, Menjivar Oscar, Suazo Juan
Clinical Oncology, Toluca State Oncology Center, Toluca, MEX.
Clinical Oncology, Pedregal's Angels Hospital, Mexico City, MEX.
Cureus. 2023 Nov 29;15(11):e49687. doi: 10.7759/cureus.49687. eCollection 2023 Nov.
Castleman disease (CD) is a rare lymphoproliferative disorder characterized by localized (unicentric) or systemic (multicentric) lymphadenopathy. This study presents a unique case of a 29-year-old female with a rare pelvic presentation of unicentric Castleman disease, specifically the hyaline vascular variant. Despite surgical resection, an unresectable residual lesion prompted adjuvant radiotherapy and subsequent chemotherapy. The literature highlights surgical resection as the primary treatment for localized Castleman disease; however, radiotherapy and combined chemotherapy regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) have shown promise in unresectable cases, emphasizing a multidisciplinary approach. This case underscores the importance of tailoring treatment strategies for uncommon Castleman disease presentations.
卡斯特曼病(CD)是一种罕见的淋巴增生性疾病,其特征为局限性(单中心性)或全身性(多中心性)淋巴结病。本研究报告了一例独特病例,一名29岁女性患有罕见的盆腔单中心卡斯特曼病,具体为透明血管型。尽管进行了手术切除,但一个无法切除的残留病灶促使进行辅助放疗及随后的化疗。文献强调手术切除是局限性卡斯特曼病的主要治疗方法;然而,放疗以及环磷酰胺、阿霉素、长春新碱和泼尼松(CHOP)等联合化疗方案在无法切除的病例中已显示出前景,强调了多学科方法。该病例强调了针对罕见卡斯特曼病表现量身定制治疗策略的重要性。